{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:35:23Z","timestamp":1792017323137,"version":"4.4.0"},"reference-count":165,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/02"],"award-info":[{"award-number":["MC_UU_00004\/02"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019550","name":"Scheme for Promotion of Academic and Research Collaboration","doi-asserted-by":"publisher","award":["PRCNPC-NOV24\/1000010"],"award-info":[{"award-number":["PRCNPC-NOV24\/1000010"]}],"id":[{"id":"10.13039\/501100019550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.pharmr.2025.100109","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:14:48Z","timestamp":1764720888000},"page":"100109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Platelet activation, aspirin, and cancer: From basic science to clinical trials"],"prefix":"10.1016","volume":"78","author":[{"given":"Carlo","family":"Patrono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9823-2322","authenticated-orcid":false,"given":"John","family":"Burn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1419-2691","authenticated-orcid":false,"given":"Paola","family":"Patrignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth E.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.pharmr.2025.100109_bib1","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100109_bib2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jacc.2022.04.034","article-title":"Association of thromboxane generation with survival in aspirin users and nonusers","volume":"80","author":"Rade","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmr.2025.100109_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106506","article-title":"The specific deletion of cyclooxygenase-1 in megakaryocytes\/platelets reduces intestinal polyposis in ApcMin\/+ mice","volume":"185","author":"Bruno","year":"2022","journal-title":"Pharmacol Res"},{"issue":"8060","key":"10.1016\/j.pharmr.2025.100109_bib4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","article-title":"Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity","volume":"640","author":"Yang","year":"2025","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100109_bib5","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1182\/blood.2019003977","article-title":"Aspirin and antiplatelet treatments in cancer","volume":"137","author":"Tao","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100109_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/pr.56.3.3","article-title":"Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition","volume":"56","author":"Simmons","year":"2004","journal-title":"Pharmacol Rev"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100109_bib7","first-page":"633","article-title":"Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis","volume":"38","author":"Kudo","year":"2005","journal-title":"J Biochem Mol Biol"},{"key":"10.1016\/j.pharmr.2025.100109_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/503128","article-title":"PGD synthase and PGD2 in immune resposne","volume":"2012","author":"Joo","year":"2012","journal-title":"Mediators Inflamm"},{"issue":"5548","key":"10.1016\/j.pharmr.2025.100109_bib9","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.294.5548.1871","article-title":"Prostaglandins and leukotrienes: advances in eicosanoid biology","volume":"294","author":"Funk","year":"2001","journal-title":"Science"},{"issue":"suppl","key":"10.1016\/j.pharmr.2025.100109_bib10","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1194\/jlr.R800094-JLR200","article-title":"Prostanoids in health and disease","volume":"50","author":"Smyth","year":"2009","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2008.01.001","article-title":"Thromboxane A2: physiology\/pathophysiology, cellular signal transduction and pharmacology","volume":"118","author":"Nakahata","year":"2008","journal-title":"Pharmacol Ther"},{"issue":"34","key":"10.1016\/j.pharmr.2025.100109_bib13","doi-asserted-by":"crossref","first-page":"26011","DOI":"10.1016\/S0021-9258(19)74486-X","article-title":"Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2\/prostaglandin H2 receptors","volume":"268","author":"Knezevic I, Borg C, Le Breton GC","year":"1993","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1073\/pnas.91.2.504","article-title":"G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets","volume":"91","author":"Offermanns","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100109_bib15","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100109_bib16","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1172\/JCI5116","article-title":"Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2","volume":"102","author":"Thomas","year":"1998","journal-title":"J Clin Invest"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100109_bib17","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/blood-2013-05-468694","article-title":"Platelets in tissue repair: control of apoptosis and interactions with regenerative cells","volume":"122","author":"Gawaz","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100109_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.thromres.2015.05.027","article-title":"Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease","volume":"136","author":"Friedman","year":"2015","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100109_bib19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.bbalip.2014.09.016","article-title":"Cyclooxygenase inhibitors: from pharmacology to clinical read-outs","volume":"1851","author":"Patrignani","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100109_bib20","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI13241","article-title":"Regulated formation of eicosanoids","volume":"107","author":"Fitzpatrick","year":"2001","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100109_bib21","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1172\/JCI13271","article-title":"Why there are two cyclooxygenase isozymes","volume":"107","author":"Smith","year":"2001","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","article-title":"Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2","volume":"96","author":"McAdam","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"10.1016\/j.pharmr.2025.100109_bib23","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1093\/eurheartj\/ehae324","article-title":"Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease","volume":"45","author":"Patrono","year":"2024","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100109_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI200113418","article-title":"Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs","volume":"108","author":"Patrono","year":"2001","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.gastro.2004.05.001","article-title":"Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial","volume":"127","author":"Laine","year":"2004","journal-title":"Gastroenterology"},{"issue":"9894","key":"10.1016\/j.pharmr.2025.100109_bib27","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Coxib and traditional NSAID Trialists' (CNT) Collaboration;","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100109_bib28","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/194927b0","article-title":"Aggregation of blood platelets by adenosine diphosphate and its reversal","volume":"194","author":"Born","year":"1962","journal-title":"Nature"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2025.100109_bib29","first-page":"S241","article-title":"Antiplatelet drugs","volume":"147","author":"Born","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"3\u20134","key":"10.1016\/j.pharmr.2025.100109_bib30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0049-3848(80)90066-3","article-title":"Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects","volume":"17","author":"Patrono","year":"1980","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib31","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1172\/JCI112341","article-title":"Estimated rate of thromboxane secretion into the circulation of normal humans","volume":"77","author":"Patrono","year":"1986","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100109_bib32","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/01.CIR.67.6.1174","article-title":"Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease","volume":"67","author":"FitzGerald","year":"1983","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0304-4165(89)90052-4","article-title":"Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydro-thromboxane B2 in the cynomolgus monkey","volume":"992","author":"Patrignani","year":"1989","journal-title":"Biochim Biophys Acta"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100109_bib34","doi-asserted-by":"crossref","first-page":"8384","DOI":"10.1016\/S0021-9258(19)68855-1","article-title":"Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites","volume":"256","author":"Roberts","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100109_bib35","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3389\/fphar.2019.01244","article-title":"Measurement of thromboxane biosynthesis in health and disease","volume":"10","author":"Patrono","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0304-4165(89)90051-2","article-title":"Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man","volume":"992","author":"Ciabattoni","year":"1989","journal-title":"Biochim Biophys Acta"},{"issue":"25","key":"10.1016\/j.pharmr.2025.100109_bib37","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199006213222503","article-title":"Thromboxane biosynthesis and platelet function in type II diabetes mellitus","volume":"322","author":"Dav\u00ec","year":"1990","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100109_bib38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \u201cresistance.\u201d","volume":"53","author":"Santilli","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100109_bib39","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1182\/blood.2019003976","article-title":"Lessons to learn from tumor-educated platelets","volume":"137","author":"Roweth","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100109_bib40","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2022.08.006","article-title":"Detection and localization of early- and late-stage cancers using platelet RNA","volume":"40","author":"In 't Veld","year":"2022","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib41","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1161\/01.CIR.85.5.1792","article-title":"Increased thromboxane biosynthesis in type IIa hypercholesterolemia","volume":"85","author":"Dav\u00ec","year":"1992","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100109_bib42","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.288.16.2008","article-title":"Platelet activation in obese women: role of inflammation and oxidant stress","volume":"288","author":"Dav\u00ec","year":"2002","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100109_bib43","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.0000039528.49161.E9","article-title":"Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease","volume":"106","author":"Minuz","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.CIR.76.1.6","article-title":"Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes","volume":"76","author":"Nowak","year":"1987","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100109_bib45","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41416-023-02310-1","article-title":"Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial","volume":"129","author":"Joharatnam-Hogan","year":"2023","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib46","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ijc.34764","article-title":"The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E2 synthesis and platelet activation in participants of the seAFOod polyp prevention trial","volume":"154","author":"Sun","year":"2024","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/01.ATV.0000152605.64964.c0","article-title":"Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans","volume":"25","author":"Morrow","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100109_bib48","doi-asserted-by":"crossref","first-page":"9383","DOI":"10.1073\/pnas.87.23.9383","article-title":"A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism","volume":"87","author":"Morrow","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"10.1016\/j.pharmr.2025.100109_bib49","doi-asserted-by":"crossref","first-page":"14916","DOI":"10.1074\/jbc.271.25.14916","article-title":"Local amplification of platelet function by 8-Epi prostaglandin F2\u03b1 is not mediated by thromboxane receptor isoforms","volume":"271","author":"Pratic\u00f2","year":"1996","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3232","article-title":"In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance","volume":"36","author":"Santilli","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100109_bib51","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/eurheartj\/ehad868","article-title":"Thromboxane biosynthesis and future events in diabetes: the ASCEND trial","volume":"45","author":"Petrucci","year":"2024","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100109_bib52","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"ASCEND Study Collaborative Group","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jnci\/djab129","article-title":"Urinary thromboxane B2 and lethal prostate cancer in African American men","volume":"114","author":"Kiely","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharmr.2025.100109_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1520488","article-title":"Platelets as crucial players in the dynamic interplay of inflammation, immunity, and cancer: unveiling new strategies for cancer prevention","volume":"15","author":"Contursi","year":"2024","journal-title":"Front Pharmacol"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100109_bib55","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.3390\/ijms22147360","article-title":"Platelet and erythrocyte extravasation across inflamed corneal venules depend on CD18, neutrophils, and mast cell degranulation","volume":"22","author":"De La Cruz","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib56","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1067\/mai.2003.1514","article-title":"Platelets are essential for leukocyte recruitment in allergic inflammation","volume":"112","author":"Pitchford","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib57","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood-2004-06-2282","article-title":"Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation","volume":"105","author":"Pitchford","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100109_bib58","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.200702-214OC","article-title":"Allergen induces the migration of platelets to lung tissue in allergic asthma","volume":"177","author":"Pitchford","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmr.2025.100109_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105744","article-title":"Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A2 is unrestrained","volume":"170","author":"D'Agostino","year":"2021","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib60","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1572-0241.2004.04129.x","article-title":"Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications","volume":"99","author":"Danese","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pharmr.2025.100109_bib61","series-title":"Platelets in Thrombotic and Non-Thrombotic Disorders","first-page":"337","article-title":"The migration of platelets and their interaction with other migrating cells","author":"Petito","year":"2017"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100109_bib62","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1124\/jpet.119.259382","article-title":"Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice","volume":"370","author":"Sacco","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"34","key":"10.1016\/j.pharmr.2025.100109_bib63","doi-asserted-by":"crossref","first-page":"31720","DOI":"10.1074\/jbc.M104036200","article-title":"Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 \u03b2-treated human synovial fibroblasts","volume":"276","author":"Faour","year":"2001","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100109_bib64","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/PPO.0000000000000003","article-title":"An inflammatory mediator, prostaglandin E2, in colorectal cancer","volume":"19","author":"Wang","year":"2013","journal-title":"Cancer J"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00281-012-0342-8","article-title":"Multifaceted roles of PGE2 in inflammation and cancer","volume":"35","author":"Nakanishi","year":"2013","journal-title":"Semin Immunopathol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100109_bib66","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1172\/JCI22218","article-title":"Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation","volume":"114","author":"Tessner","year":"2004","journal-title":"J Clin Invest"},{"issue":"7586","key":"10.1016\/j.pharmr.2025.100109_bib67","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature17038","article-title":"Metastatic colonization by circulating tumour cells","volume":"529","author":"Massagu\u00e9","year":"2016","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100109_bib68","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/eurheartj\/ehaf269","article-title":"Weekly Journal Scan: platelet thromboxane suppression as the mechanism of the anti-metastatic effect of aspirin","volume":"46","author":"Liuzzo","year":"2025","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib70","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/mol.113.084988","article-title":"Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells","volume":"84","author":"Dovizio","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100109_bib72","first-page":"65","article-title":"Platelets: essential components of the immune system","volume":"16","author":"Ali","year":"2015","journal-title":"Curr Trends Immunol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100109_bib73","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood-2008-02-142125","article-title":"Identification of Fc\u03b3RIIA as the ITAM-bearing receptor mediating \u03b1IIb\u03b23 outside-in integrin signaling in human platelets","volume":"112","author":"Boylan","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100109_bib74","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/CIRCRESAHA.114.301611","article-title":"Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity","volume":"114","author":"Boulaftali","year":"2014","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/ATVBAHA.120.314644","article-title":"Platelet extracellular vesicles: beyond the blood","volume":"41","author":"Puhm","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100109_bib76","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/blood-2013-11-540526","article-title":"Amplification of bacteria-induced platelet activation is triggered by Fc\u03b3RIIA, integrin \u03b1IIb\u03b23, and platelet factor 4","volume":"123","author":"Arman","year":"2014","journal-title":"Blood"},{"issue":"7224","key":"10.1016\/j.pharmr.2025.100109_bib77","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nature07468","article-title":"Structural recognition and functional activation of FcgammaR by innate pentraxins","volume":"456","author":"Lu","year":"2008","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100109_bib78","doi-asserted-by":"crossref","first-page":"E1550","DOI":"10.1073\/pnas.1720553115","article-title":"Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration","volume":"115","author":"Cloutier","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100109_bib79","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/jth.12905","article-title":"Human platelet IgG Fc receptor Fc\u03b3RIIA in immunity and thrombosis","volume":"13","author":"Arman","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib80","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1182\/blood-2013-03-492447","article-title":"A novel and essential role for Fc\u03b3RIIa in cancer cell-induced platelet activation","volume":"123","author":"Mitrugno","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41419-019-1367-x","article-title":"Cancer cell-derived immunoglobulin G activates platelets by binding to platelet Fc\u03b3RIIa","volume":"10","author":"Miao","year":"2019","journal-title":"Cell Death Dis"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100109_bib82","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2014-05-575878","article-title":"Platelet 12-LOX is essential for Fc\u03b3RIIa-mediated platelet activation","volume":"124","author":"Yeung","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib83","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1021\/jm4016476","article-title":"Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase","volume":"57","author":"Luci","year":"2014","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib84","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-11-1872","article-title":"Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells","volume":"72","author":"Placke","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib85","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1038\/s41467-021-27303-7","article-title":"Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer","volume":"12","author":"Hinterleitner","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14737140.2016.1123626","article-title":"Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer","volume":"16","author":"Dang","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100109_bib87","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100109_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7911","article-title":"Platelets subvert T cell immunity against cancer via GARP-TGF\u03b2 axis","volume":"2","author":"Rachidi","year":"2017","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib89","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s12672-025-03451-w","article-title":"Neutrophil extracellular traps in tumor metastasis: mechanisms, and therapeutic implications","volume":"16","author":"Li","year":"2025","journal-title":"Discov Oncol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100109_bib90","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0006-2952(99)00158-6","article-title":"Cyclooxygenase knockout mice: models for elucidating isoform-specific functions","volume":"58","author":"Langenbach","year":"1999","journal-title":"Biochem Pharmacol"},{"issue":"7\u20138","key":"10.1016\/j.pharmr.2025.100109_bib91","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0959-8049(95)00181-H","article-title":"ApcMin: a mouse model for intestinal and mammary tumorigenesis","volume":"31A","author":"Moser","year":"1995","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100109_bib92","first-page":"4705","article-title":"Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice","volume":"60","author":"Chulada","year":"2000","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib93","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0092-8674(00)81988-1","article-title":"Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)","volume":"87","author":"Oshima","year":"1996","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100109_bib94","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues","volume":"94","author":"Thun","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100109_bib95","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jacc.2016.05.083","article-title":"Aspirin and cancer","volume":"68","author":"Patrignani","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib96","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1124\/jpet.111.190785","article-title":"Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis","volume":"341","author":"Dovizio","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib97","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/carcin\/bgn267","article-title":"Mouse models for the study of colon carcinogenesis","volume":"30","author":"Rosenberg","year":"2009","journal-title":"Carcinogenesis"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100109_bib98","first-page":"3465","article-title":"Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis","volume":"57","author":"Singh","year":"1997","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100109_bib99","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/nprot.2007.279","article-title":"An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression","volume":"2","author":"Neufert","year":"2007","journal-title":"Nat Protoc"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100109_bib100","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1053\/j.gastro.2020.05.004","article-title":"Aspirin reduces colorectal tumor development in mice and gut microbes reduce its bioavailability and chemopreventive effects","volume":"159","author":"Zhao","year":"2020","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100109_bib101","doi-asserted-by":"crossref","first-page":"32462","DOI":"10.18632\/oncotarget.8655","article-title":"Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells","volume":"7","author":"Guillem-Llobat","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100109_bib102","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s11302-024-10027-w","article-title":"Role and recent progress of P2Y12 receptor in cancer development","volume":"21","author":"Xi","year":"2025","journal-title":"Purinergic Signal"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100109_bib103","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1182\/blood-2012-06-438598","article-title":"Platelets increase the proliferation of ovarian cancer cells","volume":"120","author":"Cho","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100109_bib104","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood-2017-07-795898","article-title":"Ticagrelor breaks up the tumor-platelet party","volume":"130","author":"Mitrugno","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib105","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/cancers12010250","article-title":"Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT pathway in pancreatic cancer cells","volume":"12","author":"Elaskalani","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100109_bib106","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/cdd.2017.114","article-title":"ASK1 facilitates tumor metastasis through phosphorylation of an ADP receptor P2Y12 in platelets","volume":"24","author":"Kamiyama","year":"2017","journal-title":"Cell Death Differ"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100109_bib107","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015","volume":"3","author":"Global Burden of Disease Liver Cancer Collaboration","year":"2017","journal-title":"JAMA Oncol"},{"issue":"36","key":"10.1016\/j.pharmr.2025.100109_bib108","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.3748\/wjg.v13.i36.4839","article-title":"Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection","volume":"13","author":"Neumann-Haefelin","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100109_bib109","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/cmi.2014.124","article-title":"Chronic hepatitis B: role of anti-platelet therapy in inflammation control","volume":"12","author":"Aiolfi","year":"2015","journal-title":"Cell Mol Immunol"},{"issue":"32","key":"10.1016\/j.pharmr.2025.100109_bib110","doi-asserted-by":"crossref","first-page":"E2165","DOI":"10.1073\/pnas.1209182109","article-title":"Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B","volume":"109","author":"Sitia","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib111","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2019.218545","article-title":"Low-dose Btk inhibitors selectively block platelet activation by CLEC-2","volume":"106","author":"Nicolson","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib112","doi-asserted-by":"crossref","first-page":"C373","DOI":"10.1152\/ajpcell.00325.2015","article-title":"Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function","volume":"310","author":"Rigg","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100109_bib113","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100109_bib114","first-page":"1146","article-title":"Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3","volume":"135","author":"Mammadova-Bach","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100109_bib115","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41569-023-00854-6","article-title":"Current concepts and novel targets for antiplatelet therapy","volume":"20","author":"Gawaz","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100109_bib116","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100109_bib117","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1161\/01.CIR.0000124715.27937.78","article-title":"Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects","volume":"109","author":"Capone","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib118","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/cpt.694","article-title":"In silico modeling of the antiplatelet pharmacodynamics of low-dose aspirin in health and disease","volume":"102","author":"Giaretta","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100109_bib119","doi-asserted-by":"crossref","first-page":"13207","DOI":"10.1016\/S0021-9258(17)36820-5","article-title":"Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin","volume":"269","author":"Lecomte","year":"1994","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cpt.639","article-title":"Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer","volume":"102","author":"Patrignani","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100109_bib121","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.12637","article-title":"Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action","volume":"12","author":"Patrignani","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmr.2025.100109_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114094","article-title":"Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems","volume":"178","author":"Tacconelli","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100109_bib123","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","article-title":"Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase","volume":"311","author":"Pedersen","year":"1984","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100109_bib124","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/onc.2009.421","article-title":"The role of COX-2 in intestinal inflammation and colorectal cancer","volume":"29","author":"Wang","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmr.2025.100109_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1362217","article-title":"Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action","volume":"15","author":"Patrignani","year":"2024","journal-title":"Front Pharmacol"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100109_bib126","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib127","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","article-title":"Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial","volume":"159","author":"Cook","year":"2013","journal-title":"Ann Intern Med"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100109_bib128","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100109_bib129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jnci\/djaa114","article-title":"Effect of aspirin on cancer incidence and mortality in older adults","volume":"113","author":"McNeil","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1470-2045(19)30595-9","article-title":"Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study","volume":"21","author":"Koo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmr.2025.100109_bib131","series-title":"Low-dose aspirin for primary prevention of cancer in older adults: ASPREE after 8 years","author":"Orchard","year":"2024"},{"issue":"10152","key":"10.1016\/j.pharmr.2025.100109_bib132","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100109_bib133","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2468-1253(24)00387-X","article-title":"Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Chia","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100109_bib134","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1001\/jama.2024.4840","article-title":"Aspirin vs placebo as adjuvant therapy for breast cancer: the Alliance A011502 randomized trial","volume":"331","author":"Chen","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100109_bib135","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2504650","article-title":"Low-dose aspirin for PI3K-altered localized colorectal cancer","volume":"393","author":"Martling","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100109_bib136","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djn485","article-title":"Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials","volume":"101","author":"Cole","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100109_bib137","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A randomized trial of aspirin to prevent colorectal adenomas","volume":"348","author":"Baron","year":"2003","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100109_bib138","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1001\/jama.297.21.2351","article-title":"Folic acid for the prevention of colorectal adenomas: a randomized clinical trial","volume":"297","author":"Cole","year":"2007","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100109_bib139","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer","volume":"348","author":"Sandler","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib140","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0016-5085(03)00887-4","article-title":"Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial","volume":"125","author":"Benamouzig","year":"2003","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100109_bib141","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.122.001631","article-title":"Cyclooxygenase inhibitors and cancer: the missing pieces","volume":"386","author":"Patrono","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100109_bib142","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","article-title":"Celecoxib for the prevention of sporadic colorectal adenomas","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100109_bib143","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1053\/j.gastro.2006.08.079","article-title":"A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas","volume":"131","author":"Baron","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib144","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J Clin Invest"},{"issue":"7553","key":"10.1016\/j.pharmr.2025.100109_bib145","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100109_bib146","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1136\/gutjnl-2013-305827","article-title":"The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial","volume":"63","author":"Ishikawa","year":"2014","journal-title":"Gut"},{"issue":"10164","key":"10.1016\/j.pharmr.2025.100109_bib147","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1016\/S0140-6736(18)31775-6","article-title":"Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 \u00d7 2 factorial trial","volume":"392","author":"Hull","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100109_bib148","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1053\/j.gastro.2015.09.010","article-title":"Aspirin, calcitriol, and calcium do not prevent adenoma recurrence in a randomized controlled trial","volume":"150","author":"Pommergaard","year":"2016","journal-title":"Gastroenterology"},{"issue":"9809","key":"10.1016\/j.pharmr.2025.100109_bib149","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial","volume":"378","author":"Burn","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib150","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0092-8674(93)90546-3","article-title":"The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer","volume":"75","author":"Fishel","year":"1993","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100109_bib151","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1056\/NEJMoa0801297","article-title":"Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome","volume":"359","author":"Burn","year":"2008","journal-title":"N Engl J Med"},{"issue":"10240","key":"10.1016\/j.pharmr.2025.100109_bib152","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100109_bib153","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv170","article-title":"Aspirin, ibuprofen, and the risk of colorectal cancer in Lynch syndrome","volume":"107","author":"Ait Ouakrim","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"31","key":"10.1016\/j.pharmr.2025.100109_bib154","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2014.58.9952","article-title":"Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study","volume":"33","author":"Movahedi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9678","key":"10.1016\/j.pharmr.2025.100109_bib155","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists' (ATT) Collaboration","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib156","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9759","key":"10.1016\/j.pharmr.2025.100109_bib157","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"issue":"9826","key":"10.1016\/j.pharmr.2025.100109_bib158","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100109_bib159","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cct.2016.10.004","article-title":"ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours","volume":"51","author":"Coyle","year":"2016","journal-title":"Contemp Clin Trials"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100109_bib160","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal cancer survival","volume":"367","author":"Liao","year":"2012","journal-title":"N Eng J Med"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100109_bib161","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.clon.2015.11.008","article-title":"PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. a systematic review and meta-analysis of epidemiological studies","volume":"28","author":"Paleari","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.pharmr.2025.100109_bib162","author":"Burdett"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100109_bib163","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1056\/NEJMcibr2502386","article-title":"Understanding how aspirin prevents metastasis","volume":"393","author":"Langley","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100109_bib164","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.cgh.2018.12.012","article-title":"Clopidogrel and low-dose aspirin, alone or together, reduce risk of colorectal cancer","volume":"17","author":"Rodr\u00edguez-Miguel","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2025.100109_bib165","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2024.49","article-title":"Cardio-oncology: emerging concepts in cardiovascular sequelae of cancer therapies, translational research and reverse cardio-oncology","volume":"20","author":"Camilli","year":"2025","journal-title":"Eur Cardiol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725075180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725075180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:37:14Z","timestamp":1773970634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725075180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":165,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0031699725075180"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100109","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet activation, aspirin, and cancer: From basic science to clinical trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100109"}}